Pharmacologic Substance
Trump pledges his support for a change to the IRA long sought by drugmakers
IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare
Novartis Halts Phase 2 Osteoarthritis Study of ADAMTS-5 Inhibitor Due to Lack of Pain Relief
Novartis, phase 2 trial, osteoarthritis, knee pain, ADAMTS-5 inhibitor, QUC398, M6495, clinical trial termination, pain relief, cartilage degradation, drug development
Sanofis $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II
Asthma, Amlitelimab, Kymab, sanofi, Immunology
Sanofi tempers its OX40 expectations in asthma after mid-stage miss
Asthma, Amlitelimab, TNFRSF4 gene, sanofi, exacerbations, Subgroup A Nepoviruses, Expectations
J&J brushes off tariff headwinds with raised forecast, oncology surge
J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions
Sanofi backs $90M financing for I&I biologic developer
sanofi, Series, financing characteristics, II
Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition
Camzyos, Hypertrophic Cardiomyopathy, Myers, Hypertrophic cardiomyopathy without obstruction, Obstructed, Clinical Trials
Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly
Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High
Merck inks $493M biobucks deal to use Cyprumed’s tech to create oral peptides
Cyprumed, Merck, biobucks, Peptides
Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives
Interleukin-2, Mural Oncology, Mural, strategic alternatives, Nemvaleukin Alfa, 90%